Novartis pays $678 million to settle US kickback allegationsAnother nail has been hammered into the coffin of the pharma model of providing lavish entertainment and other Share XNovartis pays $678 million to settle US kickback allegationshttps://pharmaphorum.com/news/novartis-pays-678-million-to-settle-us-kickback-allegations/
Takeda to make $200m loss after Novartis’ dry-eye drug hits trouble in EuropeNovartis’ decision to withdraw a European filing for its dry-eye drug Xiidra is to have a knock-on effect on Takeda, causing Share XTakeda to make $200m loss after Novartis’ dry-eye drug hits trouble in Europehttps://pharmaphorum.com/news/takeda-to-make-200m-loss-after-novartis-dry-eye-drug-hits-trouble-in-europe/
Novartis, Alcon settle US bribery charges with £347 million payoutNovartis and eyecare spinout Alcon have agreed to settle bribery charges brought by the US federal authorities, focused Share XNovartis, Alcon settle US bribery charges with £347 million payouthttps://pharmaphorum.com/news/novartis-alcon-settle-us-bribery-charges-with-347-million-payout/
NICE says no to Novartis’ Mayzent in secondary progressive MSThere isn’t enough evidence to back the use of Novartis Mayzent for secondary progressive multiple sclerosis on the Share XNICE says no to Novartis’ Mayzent in secondary progressive MShttps://pharmaphorum.com/news/nice-says-no-to-novartis-mayzent-in-secondary-progressive-ms/
Accessibility app wins Novartis multiple sclerosis innovation prizeCanadian start-up AccessNow has won first prize in a Novartis competition to find technological ways to help people Share XAccessibility app wins Novartis multiple sclerosis innovation prizehttps://pharmaphorum.com/news/accessibility-app-wins-novartis-multiple-sclerosis-innovation-prize/
Germany first in EU to get Novartis’ SMA gene therapy, costing almost 2m eurosNovartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) in Germany at the start of July priced Share XGermany first in EU to get Novartis’ SMA gene therapy, costing almost 2m euroshttps://pharmaphorum.com/news/novartis-eyes-smart-deal-for-sma-gene-therapy-in-uk/
After Celgene deal, BMS shoots up pharma market cap rankingsBristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies Share XAfter Celgene deal, BMS shoots up pharma market cap rankingshttps://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/
FDA extends review of Novartis’ MS drug ofatumumabThe FDA has extended its review of Novartis’ potential multiple sclerosis drug ofatumumab, pushing back a decision on the repurposed Share XFDA extends review of Novartis’ MS drug ofatumumabhttps://pharmaphorum.com/news/fda-extends-review-of-novartis-ms-drug-ofatumumab/
Novartis closes on EU approval for breast cancer drug PiqrayNovartis has moved nearer to claiming approval for its PI3K inhibitor Piqray for breast cancer in the EU, Share XNovartis closes on EU approval for breast cancer drug Piqrayhttps://pharmaphorum.com/news/novartis-closes-on-eu-approval-for-breast-cancer-drug-piqray/
